VasThera’s Drug Discovery Platform I "RedoxizymeTM"

Two natural enzymes, peroxiredoxin (Prx) and glutathione peroxidase (GPx), play a pivotal role in intracellular H2Oregulation. These enzymes are distinct due to their coupling with specific redox systems: Thioredoxin (Trx) for Prx and Glutathione (GSH) for GPx.

VasThera’s first drug discovery platform, RedoxizymeTM, can design new small-molecules of Prx nanozymes, the first-in-class drug candidates applicable for precision therapy of Prx deficiency syndrome (PDS).



VasThera’s Drug Discovery Platform I: "Opti-ATG"

Autophagy (ATG) is a critical process for maintaining cellular homeostasis by eliminating harmful aggregates and damaged organelles.

VasThera’s third drug discovery platform, Opti-ATG, can design novel scaffold compounds accelerating autophagic flux and target diseases related to autophagy, such as neurodegeneration and eye diseases.

While still in its early development stage, we expect our first-in-class drug pipeline can effectively target dry AMD.


검색 닫기